40 billion anti-digestion ulcer drug TOP10 products out! New products are coming, collecting and swarming.

With the East Sunshine drug Aisomeprazole magnesium intestinal capsule, Betde Pharmaceutical injection of Aiomeprazole sodium has been approved, as well as a number of local band procurement of proton pump inhibitor drugs included, proton pump inhibitors again attracted market attentionAccording to The Net, sales of anti-peptic ulcer drugs at the end of public medical institutions in China in 2019 were RMB39,966 millionAnti-peptic ulcer drug products TOP10 are proton pump inhibitors, and sales are more than 1 billion yuan; in brand TOP10, Osekang's injectable omeprazole sodium with sales of 2.764 billion yuan ranked first, Zhengda Qing Pharmaceutical Group's injection of ameme ameprazole sales led with a growth rate of 23.28 percentAt present, Wuhan City, Fujian Province, Shandong Province, Jiangxi Province, Qinghai Province and other 6 regions will be PPI drugs included in the volume of procurement listrecently, The East Sunshine Drug's Esomeprazole magnesium intestinal capsule, Zhejiang Bede Pharmaceuticals injection of aiomeprazole sodium has been approved by the State Drug Administration for production, proton pump inhibitors (PPI) again by the market attentionAccording to the data of The Inner Net, a total of 11 proton pump inhibitor drugs have been approved in the domestic market so far in 2020, involving 3 varieties of injection of esiomeprazole, injection of lansola, aiomeprazole and other 3 varieties, and Lepu Pharmaceuticals is the only enterprise approved for 2 varietiesthe proton pump inhibitor drug approved to date in 2020
Essomeprazole is the first clinically applied optical isomed body pump inhibitor, mainly used in the treatment of gastric ulcers, duodenal ulcers, peptic esophagitis and gastritisAiomeprazole was first developed by AstraZeneca, where its intestinal tablets were listed in the United States in 2001 and its injections in the United States in 2005At present, the domestic market editing form of Esomeprazole includes injections, intestinal tablets, intestinal lysis capsules2020 to date, six companies have been approved for injection of Aiomeprazole sodium, With bet Pharmaceuticals, Lepu Pharmaceuticals, Nanjing Kofiping, Asia Pacific Pharmaceuticals, Shanghai Huilun and Zhuotai PharmaceuticalsEast Sunshine medicine approved aiomeprazole magnesium intestinal capsule seismovana is the first and exclusive variety in China, as is the same through the consistency evaluationaccording to-MinetSales of Aiomeprazole at the terminal of Public Medical Facilities in China in 2019 were RMB5.375 billion, up 15.71% YoYAmong them, injections accounted for 61.71 percent of the market share, intestinal tablets accounted for 31.46 percent, intestinal capsules accounted for 6.83 percent, AstraZeneca accounted for 63.23 percent of the market share, Zhengda Qing Pharmaceutical Group accounted for 21.07 percent, Oseikang accounted for 6.83 percentthe sales of Aiomeprazole (units: 10,000 yuan) in the terminal of China's public medical institutions (units: 10,000 yuan) lansorazole as the first generation of proton pump inhibitors, a benzene and methase derivatives, is after omeprazole, another strong and effective proton pump inhibitor Lansoraawas was developed by Takeda and launched in the United States in 2004 with the injection of Lansora At present, Lansorafen domestic market forms include injections, intestinal tablets, intestinal capsules, tablets, capsules 2020, three companies with the injection of Lansolaahave have been approved for production, namely, Rohingya Pharmaceuticals, Lepu Pharmaceuticals and Dijon Pharmaceuticals, a subsidiary of Rohingya Pharmaceuticals At present, a total of 25 pharmaceutical companies in the domestic market have injection lansolarazole production approval According to Minet.com, sales of Lansorafen, the terminal of Public Medical Institutions in China, in 2019 amounted to 4.357 billion yuan, with injections accounting for 74.5% of the market share From the enterprise pattern, Luoxin Pharmaceuticals accounted for 25.42 percent of the market share, Orsaikang accounted for 20.28 percent, Yuekang Pharmaceuticals accounted for 12.08 percent sales of Lansoraa, a terminal of public medical institutions in China (units: 10,000 yuan), Digestive disease is a more common disease, the course of the disease has the characteristics of chronic and recurrent, the main diseases include acute gastritis, chronic gastritis, peptic ulcers, functional indigestion, and functional indigestion and peptic ulcers are the most common According to Minnet.com, sales of peptic ulcer drugs were 39.966 billion yuan in 2019 in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (china's public medical institutions), up 1.01% year-on-year the sale of peptic ulcer drugs at the end of public medical institutions in China (units: 10,000 yuan) proton pump inhibitors are commonly used drugs for anti-peptic ulcers At present, the domestic has been approved for the market of proton pump inhibitors are Aiomeprazole, omeprazole, Lansoola, Rebella, pyroprazole, eprazole and other 6 kinds As PPI drugs and related products in the domestic market has entered a mature period, and innovative drugs, anti-peptic ulcer drug market growth rate in recent years continued to slow 2019 in China's public medical institutions terminal anti-peptic ulcer drug products TOP10, proton pump inhibitors dominate the list, and sales are more than 1 billion yuan, of which Aiomeprazole magnesium intestinal tablet manufacturers only the original research AstraZenia Sales of sodium in injection and lansola for injection decreased by more than 15% Injection sales of rebella sodium led the growth of 25.51 percent, with only Osekon, Rohingya Pharmaceuticals and Chang'ao Pharmaceuticals 2019 China's public medical institutions terminal treatment peptic ulcer drug products TOP10 anti-peptic ulcer drug brand TOP10, Osecon and AstraZenico have 2 brands on the list, sales of more than 1 billion yuan of brands have 7 Osekang's injection-using omeprazole sodium topped the list with sales of 2.764 billion yuan, Zhengda Qing Pharmaceutical Group's injection-using aiomeprazole sales led by 23.28 percent growth rate, and Lizhu Group's exclusive product, Apraazole, sales of eprazole tablets also performed well 2019 China's public medical institutions terminal treatment peptic ulcer drug brand TOP10 By 2020, provincial and local drug-belt procurement will be in full bloom The database of the inner net consistency evaluation shows that the proton pump inhibitor drugs have 7 drugs (2 varieties) through the consistency evaluation, omeprazole intestinal lysis capsule evaluation enterprises have reached 4, respectively, Yangzijiang Pharmaceutical Group, Luoxin Pharmaceuticals, Hailing Pharmaceuticals, Changzhou four drugs Although proton pump inhibitor drugs were not included in the first and second batch of varieties list, but many regions of the band procurement list has been proton pump inhibitor drugs included PPI drugs through consistency evaluation enterprises May 26, Qinghai Provincial Medical Security Bureau issued a letter, intended to focus on the purchase of 64 drugs, requiring local municipal medical institutions to report 64 drugs in 2019 actual procurement quantity and July 1, 2020 - June 30, 2021 expected purchase quantity Six proton pump inhibitors, such as Esomeprazole, Omeprazole, Lansolaazole, Rebellaazole, Pisoprazole, and Epraazole, are included in the list according to incomplete statistics, there are currently Wuhan City, Fujian Province, Shandong Province, Jiangxi Province, Qinghai Province and other 6 regions to the PPI drugs into the volume of procurement list Wuhan belt procurement only for PPI injections, other areas of the belt procurement is taking into account proton pump inhibitor oral frequently released dosage forms, injections the area of proton pump inhibitors area band procurement in Wuhan City, Fujian Province has been announced the volume procurement results, Wuhan City belt procurement of 5 proton pump inhibitors have a number of enterprises winning the bid, Osekang selected 3 varieties, AstraZeneca selected 2 varieties, Wutian, Luoxin Pharmaceuticals, Zhengda Tianqing Group and other products also have the winning bid Fujian Province drug tape procurement results have exclusive winning bid, Luoxin Pharmaceuticals, proton pump inhibitors, respectively, sea Cisco, Xinhua Pharmaceuticals the selection of the region of proton pump inhibitors
at present, the procurement of drug band in Shandong, Jiangxi and Qinghai provinces is still in progress, and the results of the selection of proton pump inhibitors and other drugs are worthy of attention As the procurement of drug tape in various regions continues to advance, more regions will include proton pump inhibitors in the collection list in the future Original title: 40 billion anti-digestion ulcer drug TOP10 products out! East Sunshine Medicine, Lepu.. New products come, collections flock to